MedTrace Logo

Regulation of the Release of Inflammatory Mediators From Blood Leukocytes

NCT00180765 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2019-07-10

No results posted yet for this study

Summary

Chronic obstructive pulmonary disease (COPD for short) involves inflammation inside the air passages of the lungs. This inflammation might be partly responsible for the shortness of breath, cough and susceptibility to chest infections that form part of COPD. Inflammation is caused, in part, by white blood cells that are attracted from the blood into the air passages. Once inside the air passages, the white blood cells may change (or 'differentiate') and release substances that produce inflammation and attract more white cells. The hypothesis is that the lifespan of these cells may also be prolonged such that they produce more inflammatory mediators and in turn perpetuate inflammation. The cycle of inflammation may damage the lungs, so we want to see what mediators are released by white blood cells and determine if we can inhibit this effect with existing and new drugs. We would also like to see the effect of these drugs on the life-span and function of white blood cells. We will compare the behaviour and characteristics of white cells with those from healthy smokers and healthy non-smokers to find out if there is anything different about cells from COPD patients.

Conditions

  • Chronic Obstructive Airway Disease
  • Healthy Volunteers

Interventions

PROCEDURE

Up to 100ml blood will be taken by venupuncture.

Sponsors & Collaborators

  • Asthma UK

    collaborator OTHER

  • Imperial College London

    lead OTHER

Principal Investigators

  • Peter J Barnes, DSc · National Heart & Lung Institute, Imperial College

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-10-31
Primary Completion
2007-02-28
Completion
2008-02-29

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00180765 on ClinicalTrials.gov